F. Hoffmann-La Roche Ltd (ROG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
F. Hoffmann-La Roche Ltd (Roche) develops drugs that improve the standard of care across major disease areas. It provides pharmaceuticals in cancer, neuroscience, infection, immunology, ophthalmology, cardiovascular and metabolism, immunology, hematology, hemophilia and respiratory disease areas. The company also provides in vitro diagnostics, tissue-based cancer diagnostics, as well as diabetes management solutions. Roche’s diagnostic products include clinical chemistry and immunoassays, molecular diagnostics, tissue diagnostics, point of care diagnostics, laboratory automation and IT solutions, urinalysis products, lab testing products, custom biotech solutions, patient self-testing products and solutions for life science. The company offers its products and services to hospitals, commercial diagnostic laboratories, healthcare professionals, researchers and pharmacists. Roche is headquartered in Basel, Switzerland.
F. Hoffmann-La Roche Ltd Key Recent Developments
Feb 01,2017: Roche reports good results in 2016
Dec 05,2016: Changes in Roche Board of Directors
Nov 21,2016: Roche launches DISCOVERY 5-Plex procedure for cancer research applications
Nov 14,2016: Roche launches imCORE, a global network of cancer immunotherapy centers of excellence
Nov 07,2016: Roche launches new RNA HyperPrep product line
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
F. Hoffmann-La Roche Ltd - Key Facts 6
F. Hoffmann-La Roche Ltd - Key Employees 7
F. Hoffmann-La Roche Ltd - Key Employee Biographies 8
F. Hoffmann-La Roche Ltd - Major Products and Services 9
F. Hoffmann-La Roche Ltd - Pharmaceutical Pipeline Products Data 14
F. Hoffmann-La Roche Ltd, Pipeline Products by Therapy Area 14
F. Hoffmann-La Roche Ltd, Pipeline Products by Development Phase 16
F. Hoffmann-La Roche Ltd - History 17
F. Hoffmann-La Roche Ltd - Company Statement 34
F. Hoffmann-La Roche Ltd - Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Section 2 – Company Analysis 47
F. Hoffmann-La Roche Ltd - Business Description 47
Business Description - Diagnostics 47
Diagnostics - Overview 47
Diagnostics - Financials 47
Business Description - Pharmaceuticals 48
Pharmaceuticals - Overview 48
Pharmaceuticals - Financials 48
F. Hoffmann-La Roche Ltd - Corporate Strategy 49
F. Hoffmann-La Roche Ltd - SWOT Analysis 50
SWOT Analysis - Overview 50
F. Hoffmann-La Roche Ltd - Strengths 50
F. Hoffmann-La Roche Ltd - Weaknesses 51
F. Hoffmann-La Roche Ltd - Opportunities 52
F. Hoffmann-La Roche Ltd - Threats 54
F. Hoffmann-La Roche Ltd - Key Competitors 55
Section 3 – Company Financial Ratios 56
Financial Ratios - Capital Market Ratios 56
Financial Ratios - Annual Ratios 57
Performance Chart 59
Financial Performance 59
Financial Ratios - Interim Ratios 60
Financial Ratios - Ratio Charts 61
Section 4 – Company’s Lifesciences Financial Deals and Alliances 62
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 62
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 63
F. Hoffmann-La Roche Ltd, Recent Deals Summary 64
Section 5 – Company’s Recent Developments 65
Feb 01, 2017: Roche reports good results in 2016 65
Dec 05, 2016: Changes in Roche Board of Directors 68
Nov 21, 2016: Roche launches DISCOVERY 5-Plex procedure for cancer research applications 69
Nov 14, 2016: Roche launches imCORE, a global network of cancer immunotherapy centers of excellence 70
Nov 07, 2016: Roche launches new RNA HyperPrep product line 71
Oct 20, 2016: Roche delivers good sales growth in the first nine months of 2016 72
Aug 02, 2016: Roche introduces virtual reality theater at AACC 2016 Clinical Lab Expo to give lab professionals firsthand glimpse of connected lab of the future 75
Aug 02, 2016: Roche launches new target enrichment systems for genetic and translational research 76
Jul 29, 2016: Roche comments on new Cancer Drugs Fund 77
Jul 21, 2016: Roche delivers continued growth in the first half of 2016 78
Section 6 – Appendix 80
Methodology 80
Ratio Definitions 80
About GlobalData 84
Contact Us 84
Disclaimer 84List of Tables
F. Hoffmann-La Roche Ltd, Key Facts 6
F. Hoffmann-La Roche Ltd, Key Employees 7
F. Hoffmann-La Roche Ltd, Key Employee Biographies 8
F. Hoffmann-La Roche Ltd, Major Products and Services 9
F. Hoffmann-La Roche Ltd, Number of Pipeline Products by Therapy Area 14
F. Hoffmann-La Roche Ltd, Number of Pipeline Products by Therapy Area (Cont...1) 15
F. Hoffmann-La Roche Ltd, Number of Pipeline Products by Development Stage 16
F. Hoffmann-La Roche Ltd, History 17
F. Hoffmann-La Roche Ltd, Subsidiaries 36
F. Hoffmann-La Roche Ltd, Key Competitors 55
F. Hoffmann-La Roche Ltd, Ratios based on current share price 56
F. Hoffmann-La Roche Ltd, Annual Ratios 57
F. Hoffmann-La Roche Ltd, Annual Ratios (Cont...1) 58
F. Hoffmann-La Roche Ltd, Interim Ratios 60
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 62
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 63
F. Hoffmann-La Roche Ltd, Recent Deals Summary 64
Currency Codes 80
Capital Market Ratios 80
Equity Ratios 81
Profitability Ratios 81
Cost Ratios 82
Liquidity Ratios 82
Leverage Ratios 83
Efficiency Ratios 83List of Figures
F. Hoffmann-La Roche Ltd, Pipeline Products by Therapy Area 14
F. Hoffmann-La Roche Ltd, Pipeline Products by Development Phase 16
F. Hoffmann-La Roche Ltd, Performance Chart (2012 - 2016) 59
F. Hoffmann-La Roche Ltd, Ratio Charts 61
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 62
F. Hoffmann-La Roche Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 63
Zentiva SA
Takeda Pharmaceutical Company Ltd
Sanofi
Pfizer Inc
Novartis AG
Merck & Co Inc
Johnson & Johnson
GTx Inc
GlaxoSmithKline Plc
Eli Lilly and Company
Danish Pain Research Center
Bristol-Myers Squibb Company
BioThema AB
Becton Dickinson and Co
Bayer AG
AstraZeneca Plc
Astellas Pharma Inc
Amgen Inc
Abbott Laboratories
Abaxis Inc
